GSK Divests Non-Core OTCs To Focus On "Priority Brands," Emerging Markets
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline will divest non-core OTC products to accelerate consumer health care growth and help fund a share buy-back program following a financial wipeout in the firm's most recent quarter.
You may also be interested in...
Central, Eastern Europe Lead OTC Growth On Sector's Top Continent
Central and Eastern Europe continue to drive OTC sales growth on the continent, with even low-growth countries matching the best levels in Western Europe
Central, Eastern Europe Lead OTC Growth On Sector’s Top Continent
Central and Eastern Europe continue to drive OTC sales growth on the continent, with even low-growth countries matching the best levels in Western Europe.
Central, Eastern Europe Lead OTC Growth On Sector’s Top Continent
Central and Eastern Europe continue to drive OTC sales growth on the continent, with even low-growth countries matching the best levels in Western Europe.